Heartland Bank & Trust Co Invests $791,000 in Intuitive Surgical, Inc. $ISRG

Heartland Bank & Trust Co bought a new position in Intuitive Surgical, Inc. (NASDAQ:ISRG) during the second quarter, according to its most recent filing with the SEC. The firm bought 1,988 shares of the medical equipment provider’s stock, valued at approximately $791,000.

Several other hedge funds have also bought and sold shares of the business. State Street Corp lifted its stake in shares of Intuitive Surgical by 1.0% in the fourth quarter. State Street Corp now owns 15,701,591 shares of the medical equipment provider’s stock valued at $8,892,753,000 after buying an additional 162,264 shares in the last quarter. Capital World Investors raised its holdings in shares of Intuitive Surgical by 1.7% in the 4th quarter. Capital World Investors now owns 7,856,018 shares of the medical equipment provider’s stock worth $4,449,491,000 after acquiring an additional 127,526 shares during the last quarter. Norges Bank bought a new position in Intuitive Surgical in the 4th quarter valued at about $2,856,987,000. Invesco Ltd. boosted its stake in Intuitive Surgical by 17.4% during the 4th quarter. Invesco Ltd. now owns 4,128,735 shares of the medical equipment provider’s stock valued at $2,338,350,000 after purchasing an additional 611,268 shares during the last quarter. Finally, Bank of America Corp DE increased its holdings in Intuitive Surgical by 3.3% during the 1st quarter. Bank of America Corp DE now owns 3,616,973 shares of the medical equipment provider’s stock worth $1,667,388,000 after purchasing an additional 116,292 shares in the last quarter. Institutional investors and hedge funds own 83.64% of the company’s stock.

Insiders Place Their Bets

In other Intuitive Surgical news, Director Gary S. Guthart sold 10,000 shares of the business’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $400.00, for a total value of $4,000,000.00. Following the sale, the director directly owned 1,245,679 shares in the company, valued at $498,271,600. The trade was a 0.80% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Amy L. Ladd sold 72 shares of the company’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $393.10, for a total value of $28,303.20. Following the transaction, the director directly owned 179 shares in the company, valued at $70,364.90. This represents a 28.69% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 17,283 shares of company stock valued at $7,015,429. Company insiders own 0.60% of the company’s stock.

Key Headlines Impacting Intuitive Surgical

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: Operating margin is widening. Intuitive Surgical’s operating margin has expanded in each of the past three years, suggesting improving efficiency and earnings quality even as U.S. procedure growth moderates. Intuitive Surgical Stock Has Fallen While Its Operating Margin Keeps Widening
• Positive Sentiment: Wall Street remains broadly constructive. Analysts generally view ISRG favorably, with a consensus “Moderate Buy” rating and price targets substantially above recent trading levels. Recent upgrades and bullish commentary point to confidence in the da Vinci platform’s long-term growth. Is Wall Street Bullish or Bearish on Intuitive Surgical Stock?
• Positive Sentiment: Asia-Pacific capacity is expanding. A new manufacturing plant in Penang, Malaysia, is intended to increase regional capacity and support demand for robotic-assisted surgery, strengthening ISRG’s international growth opportunity. Intuitive Surgical Expands Manufacturing Footprint in Asia Pacific
• Neutral Sentiment: The company faces an execution test. Investors are weighing whether Intuitive can sustain system placements, procedure growth and recurring instrument revenue while expanding internationally and navigating a more cautious healthcare spending environment. Why Is Intuitive Surgical Facing an Execution Test?
• Negative Sentiment: Growth and valuation remain concerns. Investors continue to digest management’s cautious procedure-growth outlook of roughly 13.5%–15.5% for 2026, along with an estimated tariff impact on gross margin. With ISRG trading well below its prior high but still at a premium earnings multiple, valuation compression may continue if growth slows further. Intuitive Surgical Slides as Investors Digest Cautious Outlook
• Negative Sentiment: Insider selling adds a modest overhang. An executive vice president sold a small position under a pre-arranged Rule 10b5-1 plan. The transaction is not necessarily a fundamental warning, but broader recent insider activity has consisted predominantly of sales rather than purchases. Why Is Intuitive Surgical Stock Trending After Hours?

Intuitive Surgical Price Performance

Shares of NASDAQ:ISRG opened at $378.81 on Friday. The company has a market capitalization of $133.83 billion, a PE ratio of 43.39, a price-to-earnings-growth ratio of 2.71 and a beta of 1.46. The business has a fifty day moving average price of $388.47 and a two-hundred day moving average price of $436.69. Intuitive Surgical, Inc. has a 1 year low of $328.57 and a 1 year high of $603.88.

Intuitive Surgical (NASDAQ:ISRG) last announced its quarterly earnings data on Thursday, July 16th. The medical equipment provider reported $2.80 EPS for the quarter, topping the consensus estimate of $2.48 by $0.32. The business had revenue of $2.89 billion for the quarter, compared to analyst estimates of $2.83 billion. Intuitive Surgical had a net margin of 28.45% and a return on equity of 16.91%. The company’s revenue for the quarter was up 18.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.81 earnings per share. Sell-side analysts anticipate that Intuitive Surgical, Inc. will post 8.87 earnings per share for the current year.

Wall Street Analysts Forecast Growth

ISRG has been the subject of several analyst reports. BTIG Research lowered their price objective on Intuitive Surgical from $512.00 to $469.00 and set a “buy” rating for the company in a research note on Friday, July 17th. Robert W. Baird decreased their price target on Intuitive Surgical from $525.00 to $500.00 and set an “outperform” rating for the company in a report on Friday, July 17th. Stifel Nicolaus lowered their price target on Intuitive Surgical from $670.00 to $550.00 and set a “buy” rating for the company in a research report on Friday, July 17th. KeyCorp reaffirmed an “overweight” rating on shares of Intuitive Surgical in a report on Wednesday, August 12th. Finally, Bank of America reduced their target price on shares of Intuitive Surgical from $520.00 to $515.00 in a research note on Friday, June 12th. Twenty-two research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $508.68.

Intuitive Surgical Profile

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.